Coming up with a treatment or cure for any disease is hard enough, clinically speaking. But when you factor in the bureaucratic and financial obstacles involved, it can be downright daunting. FasterCures, a self-described “action tank,” is trying to accelerate the treatment-development process by bringing together researchers, businesspeople and foundations to share ideas and resources.
Continue Reading…
Archive for the Research Category
When the Baltimore Orioles’ Adam Jones makes a great catch — a feat the Gold Glove centerfielder accomplishes on a regular basis — he isn’t thinking about his retinas. But in the five seconds it takes a baseball to leave an opponent’s bat and reach Jones’ glove, his retinas are processing an enormous amount of real-time visual information — continual changes in the contrast, velocity and trajectory of the ball as it rockets out of the infield, reaches high into the stadium lights (or the sun) and descends into the outfield.
Continue Reading…
Every field of research has its “rock stars,” specialists so revered for their knowledge, expertise and experience, they’re famous in certain circles worldwide. And when it comes to retinal-disease research, the stars are invariably linked to the Foundation Fighting Blindness, which either funds or has funded their vision-saving work. So, after interviewing a handful of them recently, we’ve put together a few research-oriented playlists on our revamped YouTube page.
Continue Reading…
Julie Anderson admits she’s stubborn. “It’s the German in me,” she says. “I don’t ever give in.” So when she was diagnosed with retinitis pigmentosa, or RP, a hereditary disease that progressively diminishes eyesight, the mother of three didn’t crawl into a hole. She joined FFB and, for more than a dozen years, has been its Minneapolis chapter’s president. And when she heard, in the mid 2000s, that the company Neurotech would be conducting a Foundation-funded clinical, or human, trial for a treatment of RP at the University of Minnesota, she was literally the first in line to be screened for approval. Continue Reading…
As the Foundation reported back in February, the Argus II retinal prosthesis, developed by Second Sight Medical Products, received marketing approval from the U.S. Food and Drug Administration.
For those of us on the front lines of fighting blindness — whether we’re raising funds, conducting research or stand to personally benefit from the results — the device’s approval is one of the most exciting milestones in vision restoration ever achieved.
Continue Reading…
As I wind down the week at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), I’d like to introduce an intriguing therapeutic approach to retinal degeneration that would be a home run if perfected. It’s called retinal regeneration, and it happens to be right in line with the National Eye Institute’s life-changing audacious goal, announced on Monday: “to regenerate the neurons and neural connections in the eye and visual system.”
Continue Reading…
One of the promising emerging approaches to restoring vision in people with advanced retinal diseases is a form of therapy known as optogenetics. In essence, this type of treatment restores light sensitivity — and, potentially, meaningful vision — to people who have very little, if any, vision remaining. An important benefit of optogenetics is that it should work regardless of the underlying genetic defect causing the disease. While it is too early to speculate how well optogenetics will ultimately work, we’re hoping it ends up retiring a lot of white canes. Continue Reading…
I am always pleased to hear reports on human studies for retinal diseases. And such is the case with a research poster I just reviewed at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. It described a new clinical trial underway for a potentially life-changing gene therapy for people with autosomal recessive retinitis pigmentosa (MERTK mutations) taking place at King Khaled Eye Specialist Hospital in Saudi Arabia.
Continue Reading…
The National Eye Institute (NEI) just announced that fighting blindness — retinal degenerations, in particular — has gotten audacious. It’s potentially life-changing news for people with these difficult conditions.
Continue Reading…
I am excited to be reporting to you live from Seattle where about 10,000 of the world’s top eye researchers are convening for the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). While researchers from many different ophthalmic fields are present at ARVO, it is the world’s largest gathering of retinal scientists. Continue Reading…
Steve is highly respected for his expertise and tireless commitment to finding treatments and cures for vision-robbing retinal diseases. 
As the Foundation's senior science writer, Ben writes science and research articles for the Foundation’s website, newsletters and Eye on the Cure blog. 
As the Foundation's senior writer, Rich writes and edits content for all of the Foundation’s print and online publications, including its blog, Eye on the Cure. 